Bio-Techne (TECH) has expanded its COMET spatial biology platform with new SPYRE Focus Panels, SPYRE Amplification Kits, and updated HORIZON image analysis tools, a product move that matters for the ...
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets ...
StockStory.org on MSN
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne stocks trade down, what you need to know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...
Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...
(Reuters) - Bio-Techne missed Wall Street expectations for first-quarter profit on Tuesday, as a persisting funding crunch among its biotech clients weighed on demand for its diagnostic products and ...
Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2025-11-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...
Shares of Bio-Techne Corp. TECH rallied 2.14% to $52.04 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.11% ...
MINNEAPOLIS, April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BMP ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results